OCEANS data add weight to Roche case for Avastin in ovarian cancer
This article was originally published in Scrip
Executive Summary
Avastin (bevacizumab) has now met the primary endpoint in three Phase III ovarian cancer trials. While Roche is currently seeking first-line approval for the IgG1 humanised monoclonal antibody against vascular endothelial growth factor (VEGF) as a treatment for ovarian cancer in Europe on the basis of the GOG-218 and ICON7 trial data (www.scripintelligence.com, 7 June, 2010 and 2 July, 2010, respectively), the results of the OCEANS trial, unveiled at the American Society of Clinical Oncology annual meeting 2011, show that Avastin can benefit patients in the second-line setting where it may be extensively used if approved for the indication.